Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.
Our trusted Pharma Intelligence brands
HBW Insight
Nestlé Health Science is expanding its CBD offering outside the US with the UK launch of a dietary supplement formulated by cannabis development firm Geocann.
Medtech Insight
The Cumberlege Review of patient safety delivered a damning verdict on the UK’s health system. Its recommendations must be acted on, says a consensus of stakeholders.
Topic Policy & Regulation Medtech
Medtech Insight
FDA clearance of the ASD Diagnostic app could lead to early diagnosis, improving quality of life of children with ASD and their caregivers.
Topic Diagnostics Digital Health FDA
Generics Bulletin
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
Scrip
Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.
Scrip
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
Topic Coronavirus
Generics Bulletin
The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.
Pink Sheet
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
Topic US Election 2020 Drug Pricing
Pink Sheet
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Topic US Election 2020 Drug Pricing
Pink Sheet
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Topic US Election 2020 Drug Pricing
Biomedtracker, Datamonitor Healthcare
Valuable insight and expert analyst commentary 2021’s expected drug launches, their indications, commercial potential, regulatory catalysts and more.
Pink Sheet
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Topic US Election 2020 FDA
Scrip
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.
Topic Coronavirus Vaccines
Scrip
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Scrip
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.
Pink Sheet
28 Sep 2020
Pink Sheet
28 Sep 2020
Generics Bulletin
28 Sep 2020
Pink Sheet
28 Sep 2020
Scrip
28 Sep 2020
Medtech Insight
28 Sep 2020
Scrip
28 Sep 2020
Generics Bulletin
28 Sep 2020
Medtech Insight
28 Sep 2020
Generics Bulletin
28 Sep 2020
Generics Bulletin
28 Sep 2020
Scrip
27 Sep 2020
Pink Sheet
27 Sep 2020
HBW Insight
27 Sep 2020
Pink Sheet
27 Sep 2020
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
06 Oct 2020 , 16:00
Webinar
12 Oct 2020 , 09:00
USA
Conference
03 Nov 2020 , 09:00
Awards
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date